Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...

Scotiabank analyst George Farmer lowered the firm’s price target on Syndax (SNDX) to $18 from $23 and keeps a Sector Perform rating on ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...

Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price target boosted by HC Wainwright from $45.00 to $47.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have been given a consensus recommendation of ...

Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial ...